（原标题：【券商聚焦】浦银国际维持药明合联(2268.HK)“买入”评级 目标价75港元）金吾财讯|浦银国际发布研报指，药明合联(2268.HK)2025年初步业绩符合预期，维持“买入”评级，目标价75港元。报告显示，公司2025年收入同比增长超45%，归母净利润增长超38%，毛利率达35.8%高于预期。公司新签70个iCMC项目，其中超50%来自新型ADC贡献。 公司首次披露2025-2030...
Source Link（原标题：【券商聚焦】浦银国际维持药明合联(2268.HK)“买入”评级 目标价75港元）金吾财讯|浦银国际发布研报指，药明合联(2268.HK)2025年初步业绩符合预期，维持“买入”评级，目标价75港元。报告显示，公司2025年收入同比增长超45%，归母净利润增长超38%，毛利率达35.8%高于预期。公司新签70个iCMC项目，其中超50%来自新型ADC贡献。 公司首次披露2025-2030...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.